A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytopenia, Neonatal Alloimmune

Interventions

DRUG: Nipocalimab
DRUG: Intravenous immunoglobulins (IVIG)
DRUG: Prednisone

Sponsor

Janssen Research & Development, LLC